Radboud University Medical Center and Maastricht UMC+ published results describing clinical long-read genome sequencing as a route to more accurate and efficient diagnosis of rare genetic disorders. The approach uses long-read sequencing to improve variant detection and interpretation, with the report positioning it as a step toward expanding first-tier testing. The study’s clinical framing emphasizes operational impact—improving time-to-result and reducing interpretive uncertainty—rather than only incremental increases in yield. By addressing phase and novel variant identification, the work aims to make rare disease workflows more decisive. The reporting aligns with the ongoing European implementation push for long-read platforms as sequencing capacity grows and analytic pipelines mature for diagnostic-grade use.